GlassScriptPhysician profile
Andrew D Collins
NPI 1932424660
$5,050.15
in general payments reported to CMS, 2019-2025
17 companies · $829 in 2025
The $829 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $16.44 · 2021: $42.19 · 2022: $947 · 2023: $1,410 · 2024: $1,362 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,047 · Food and Beverage: $1,474 · Education: $80.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,047.00 |
| Food and Beverage | $1,474.02 |
| Education | $80.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,679.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $274.79 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $201.62 | 2024-2025 | Actimmune, Tezspire |
| Lilly USA, LLC | $130.45 | 2025 | Ebglyss |
| Genentech USA, INC. | $112.52 | 2019-2025 | Xolair |
| Horizon Therapeutics Plc | $106.29 | 2021-2023 | Actimmune |
| Grifols USA, LLC | $89.23 | 2022-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $83.98 | 2020-2025 | |
| Csl Behring | $80.60 | 2025 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $69.87 | 2025 | Neffy |
| Leo Pharma INC. | $44.94 | 2022-2025 | Anzupgo |
| Pfizer INC. | $43.94 | 2024-2025 | |
| Shire North American Group INC | $39.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.73 | 2023-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $24.84 | 2024 | Orladeyo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $17.32 | 2025 | |
| Kaleo, INC. | $15.74 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.